hVIVO PLC

  • Market Cap: Micro Cap
  • Industry: Miscellaneous
  • ISIN: GB00B9275X97
GBP
0.07
0 (-0.76%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Below par performance in long term as well as near term

  • Along with generating -68.67% returns in the last 1 year, the stock has also underperformed FTSE 100 in the last 3 years, 1 year and 3 months
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

GBP 39 Million (Micro Cap)

stock-summary
P/E

5.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.93

stock-summary
Return on Equity

23.84%

stock-summary
Price to Book

0.87

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-29.95%
0%
-29.95%
6 Months
-37.62%
0%
-37.62%
1 Year
-68.43%
0%
-68.43%
2 Years
-71.71%
0%
-71.71%
3 Years
-44.73%
0%
-44.73%
4 Years
-71.77%
0%
-71.77%
5 Years
-68.16%
0%
-68.16%

hVIVO PLC for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
79.25%
EBIT Growth (5y)
32.38%
EBIT to Interest (avg)
2.29
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
1.51
Tax Ratio
19.80%
Dividend Payout Ratio
12.74%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
103.87%
ROE (avg)
20.51%
Valuation key factors
Factor
Value
P/E Ratio
5
Industry P/E
Price to Book Value
1.20
EV to EBIT
1.27
EV to EBITDA
0.92
EV to Capital Employed
3.96
EV to Sales
0.19
PEG Ratio
NA
Dividend Yield
0.00%
ROCE (Latest)
311.61%
ROE (Latest)
23.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by hVIVO PLC"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 15.46% vs 31.44% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 2,112.50% vs -700.00% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "56.00",
          "val2": "48.50",
          "chgp": "15.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "10.20",
          "val2": "6.80",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-7.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "16.10",
          "val2": "-0.80",
          "chgp": "2,112.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "133.50%",
          "val2": "80.90%",
          "chgp": "5.26%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
56.00
48.50
15.46%
Operating Profit (PBDIT) excl Other Income
10.20
6.80
50.00%
Interest
0.20
0.10
100.00%
Exceptional Items
0.00
-7.10
100.00%
Consolidate Net Profit
16.10
-0.80
2,112.50%
Operating Profit Margin (Excl OI)
133.50%
80.90%
5.26%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 15.46% vs 31.44% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 2,112.50% vs -700.00% in Dec 2022

stock-summaryCompany CV
About hVIVO PLC stock-summary
stock-summary
hVIVO PLC
Miscellaneous
Open Orphan plc, formerly Venn Life Sciences Holdings plc, is engaged in the pharma services business. The Company is also engaged in building an orphan drug consulting services platform that helps pharma companies commercialize their products in Europe. The Company consists of four elements: a European clinical research organization and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians, and a Health Data Platform. The Company provides fragmented orphan drug services. The Company acquires and consolidates series of orphan drug services companies. It also provides digital data platforms to support companies in research & development and commercialization.
Company Coordinates stock-summary
Company Details
Queen Mary BioEnterprises, Innovation Centre, 42 New Road, LONDON None : E1 2AX
Registrar Details